ABEONA THERAPEUTICS INC. Revenue
ABEONA THERAPEUTICS INC. (ABEO) reported Revenue of $11.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $11.38M, a 2745.00% increase year-over-year.
- ABEONA THERAPEUTICS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $8.72M.
- ABEONA THERAPEUTICS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $5.42M.
- ABEONA THERAPEUTICS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00.
- ABEONA THERAPEUTICS INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $5.82M.
- ABEONA THERAPEUTICS INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $3.50M, a 147.52% increase from fiscal 2022.
- ABEONA THERAPEUTICS INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.41M, a 52.87% decline from fiscal 2021.
- ABEONA THERAPEUTICS INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $3.00M, a 70.00% decline from fiscal 2020.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.38M 10-Q · filed 2026-08-13 | $20.10M 10-Q · filed 2026-08-13 | $25.52M derived: sum of 3 quarters · filed 2026-08-13 | $25.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $8.72M 10-Q · filed 2026-05-13 | $14.14M derived: sum of 2 quarters · filed 2026-05-13 | $14.14M derived: sum of 3 quarters · filed 2026-05-13 | $14.54M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.42M derived: sum of 2 quarters · filed 2026-03-17 | $5.82M derived: sum of 3 quarters · filed 2026-08-13 | $5.82M 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $400.00K derived: sum of 2 quarters · filed 2026-08-13 | $400.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-13 | $400.00K 10-Q · filed 2026-08-13 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $3.50M derived: sum of 3 quarters · filed 2025-03-20 | $3.50M 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $3.50M derived: sum of 2 quarters · filed 2024-11-14 | $3.50M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $3.50M 10-Q · filed 2024-08-12 | $3.50M 10-Q · filed 2024-08-12 | ||
| 2022-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $68.00K derived: sum of 2 quarters · filed 2024-03-18 | $1.07M derived: sum of 3 quarters · filed 2024-03-18 | $1.41M 10-K · filed 2024-03-18 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.00M derived: sum of 2 quarters · filed 2023-11-13 | $1.35M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $1.00M 10-Q · filed 2023-08-08 | $1.35M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $346.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $3.00M 10-K · filed 2023-03-29 | |||
| 2020-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $10.00M derived: sum of 2 quarters · filed 2022-03-31 | $10.00M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $7.00M 10-Q · filed 2021-11-15 | $7.00M 10-Q · filed 2021-11-15 | ||
| 2018-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $2.19M derived: sum of 2 quarters · filed 2020-03-16 | $3.00M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $1.71M 10-Q · filed 2019-11-12 | $2.52M 10-Q · filed 2019-11-12 | ||
| 2017-12-31 | $837.00K 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |